Which has preferable earnings and valuation, MASI or VEEV?

Veeva Systems has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Masimo $1.53B 6.12 -$151.50M -$10.54 N/A Veeva Systems $3.20B 8.97 $908.91M $5.41 32.42

Is MASI or VEEV more profitable?

Veeva Systems has a net margin of 28.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Veeva Systems' return on equity. Company Net Margins Return on Equity Return on Assets Masimo 4.90% 31.33% 13.93% Veeva Systems 28.44% 13.80% 11.39%

Does the media prefer MASI or VEEV?

In the previous week, Veeva Systems had 23 more articles in the media than Masimo. MarketBeat recorded 26 mentions for Veeva Systems and 3 mentions for Masimo. Masimo's average media sentiment score of 0.82 beat Veeva Systems' score of 0.75 indicating that Masimo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Masimo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veeva Systems 11 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, RMD or MASI?

ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.48 $1.40B $10.37 18.74 Masimo $1.53B 6.12 -$151.50M -$10.54 N/A

Is RMD or MASI more profitable?

ResMed has a net margin of 27.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Masimo 4.90% 31.33% 13.93%

Does the media favor RMD or MASI?

In the previous week, ResMed had 11 more articles in the media than Masimo. MarketBeat recorded 14 mentions for ResMed and 3 mentions for Masimo. ResMed's average media sentiment score of 1.18 beat Masimo's score of 0.82 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Masimo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DXCM or MASI?

DexCom has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.08 $836.30M $2.34 31.38 Masimo $1.53B 6.12 -$151.50M -$10.54 N/A

Is DXCM or MASI more profitable?

DexCom has a net margin of 19.31% compared to Masimo's net margin of 4.90%. DexCom's return on equity of 33.33% beat Masimo's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% Masimo 4.90% 31.33% 13.93%

Does the media prefer DXCM or MASI?

In the previous week, DexCom had 25 more articles in the media than Masimo. MarketBeat recorded 28 mentions for DexCom and 3 mentions for Masimo. DexCom's average media sentiment score of 1.00 beat Masimo's score of 0.82 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 21 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Masimo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, MASI or STE?

STERIS has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Masimo $1.53B 6.12 -$151.50M -$10.54 N/A STERIS $5.94B 3.50 $782.30M $7.93 26.71

Is MASI or STE more profitable?

STERIS has a net margin of 13.18% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets Masimo 4.90% 31.33% 13.93% STERIS 13.18% 14.15% 9.52%

Does the media refer more to MASI or STE?

In the previous week, STERIS had 1 more articles in the media than Masimo. MarketBeat recorded 4 mentions for STERIS and 3 mentions for Masimo. STERIS's average media sentiment score of 0.95 beat Masimo's score of 0.82 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Masimo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Masimo (MASI) Competitors

$178.44 -0.01 (-0.01%)

As of 02:27 PM Eastern

Compare

MASI vs. AMN, VEEV, RMD, DXCM, and STE

Should you buy Masimo stock or one of its competitors? MarketBeat compares Masimo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Masimo include AMN Healthcare Services (AMN), Veeva Systems (VEEV), ResMed (RMD), DexCom (DXCM), and STERIS (STE). These companies are all part of the "medical" sector.

How does Masimo compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 9.7% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Masimo has a net margin of 4.90% compared to AMN Healthcare Services' net margin of -0.95%. Masimo's return on equity of 31.33% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Masimo	4.90%	31.33%	13.93%

In the previous week, AMN Healthcare Services had 2 more articles in the media than Masimo. MarketBeat recorded 5 mentions for AMN Healthcare Services and 3 mentions for Masimo. Masimo's average media sentiment score of 0.82 beat AMN Healthcare Services' score of -0.75 indicating that Masimo is being referred to more favorably in the news media.

Company	Overall Sentiment
AMN Healthcare Services	Negative
Masimo	Positive

AMN Healthcare Services has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Masimo has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

AMN Healthcare Services currently has a consensus target price of $25.29, indicating a potential downside of 12.19%. Masimo has a consensus target price of $180.40, indicating a potential upside of 1.10%. Given Masimo's higher probable upside, analysts clearly believe Masimo is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

AMN Healthcare Services has higher revenue and earnings than Masimo. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.41	-$95.70M	-$0.87	N/A
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A

Summary

Masimo beats AMN Healthcare Services on 9 of the 16 factors compared between the two stocks.

How does Masimo compare to Veeva Systems?

Masimo (NASDAQ:MASI) and Veeva Systems (NYSE:VEEV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Masimo has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Veeva Systems has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Veeva Systems has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A
Veeva Systems	$3.20B	8.97	$908.91M	$5.41	32.42

In the previous week, Veeva Systems had 23 more articles in the media than Masimo. MarketBeat recorded 26 mentions for Veeva Systems and 3 mentions for Masimo. Masimo's average media sentiment score of 0.82 beat Veeva Systems' score of 0.75 indicating that Masimo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veeva Systems	11 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veeva Systems has a net margin of 28.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Veeva Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
Veeva Systems	28.44%	13.80%	11.39%

86.0% of Masimo shares are owned by institutional investors. Comparatively, 88.2% of Veeva Systems shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 10.6% of Veeva Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Masimo currently has a consensus price target of $180.40, indicating a potential upside of 1.10%. Veeva Systems has a consensus price target of $276.52, indicating a potential upside of 57.66%. Given Veeva Systems' stronger consensus rating and higher possible upside, analysts plainly believe Veeva Systems is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veeva Systems	1 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Veeva Systems beats Masimo on 12 of the 16 factors compared between the two stocks.

How does Masimo compare to ResMed?

ResMed (NYSE:RMD) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

ResMed currently has a consensus target price of $286.18, indicating a potential upside of 47.25%. Masimo has a consensus target price of $180.40, indicating a potential upside of 1.10%. Given ResMed's stronger consensus rating and higher probable upside, analysts plainly believe ResMed is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.48	$1.40B	$10.37	18.74
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A

In the previous week, ResMed had 11 more articles in the media than Masimo. MarketBeat recorded 14 mentions for ResMed and 3 mentions for Masimo. ResMed's average media sentiment score of 1.18 beat Masimo's score of 0.82 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a net margin of 27.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Masimo	4.90%	31.33%	13.93%

ResMed has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Masimo has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

55.0% of ResMed shares are held by institutional investors. Comparatively, 86.0% of Masimo shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 9.7% of Masimo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ResMed beats Masimo on 12 of the 17 factors compared between the two stocks.

How does Masimo compare to DexCom?

DexCom (NASDAQ:DXCM) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

DexCom currently has a consensus target price of $82.42, suggesting a potential upside of 12.23%. Masimo has a consensus target price of $180.40, suggesting a potential upside of 1.10%. Given DexCom's stronger consensus rating and higher probable upside, equities research analysts plainly believe DexCom is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DexCom has a net margin of 19.31% compared to Masimo's net margin of 4.90%. DexCom's return on equity of 33.33% beat Masimo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Masimo	4.90%	31.33%	13.93%

DexCom has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.08	$836.30M	$2.34	31.38
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A

97.8% of DexCom shares are held by institutional investors. Comparatively, 86.0% of Masimo shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 9.7% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DexCom has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Masimo has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

In the previous week, DexCom had 25 more articles in the media than Masimo. MarketBeat recorded 28 mentions for DexCom and 3 mentions for Masimo. DexCom's average media sentiment score of 1.00 beat Masimo's score of 0.82 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	21 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Masimo on 14 of the 17 factors compared between the two stocks.

How does Masimo compare to STERIS?

Masimo (NASDAQ:MASI) and STERIS (NYSE:STE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

STERIS has a net margin of 13.18% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
STERIS	13.18%	14.15%	9.52%

86.0% of Masimo shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

STERIS has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A
STERIS	$5.94B	3.50	$782.30M	$7.93	26.71

Masimo has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, STERIS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Masimo currently has a consensus target price of $180.40, indicating a potential upside of 1.10%. STERIS has a consensus target price of $278.00, indicating a potential upside of 31.24%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe STERIS is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, STERIS had 1 more articles in the media than Masimo. MarketBeat recorded 4 mentions for STERIS and 3 mentions for Masimo. STERIS's average media sentiment score of 0.95 beat Masimo's score of 0.82 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

STERIS beats Masimo on 11 of the 16 factors compared between the two stocks.

Get Masimo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MASI vs. The Competition

Export

Metric	Masimo	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.34B	$7.16B	$6.42B	$12.58B
Dividend Yield	N/A	1.32%	2.75%	5.26%
P/E Ratio	-16.93	45.61	21.29	26.31
Price / Sales	6.12	75.60	562.18	114.16
Price / Cash	38.49	24.64	43.49	56.90
Price / Book	11.85	7.34	10.61	7.34
Net Income	-$151.50M	$158.10M	$3.56B	$336.95M
7 Day Performance	-0.21%	10.60%	3.36%	3.65%
1 Month Performance	-0.01%	13.40%	6.63%	7.39%
1 Year Performance	13.68%	4.47%	36.99%	37.74%

Masimo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MASI Masimo	1.4071 of 5 stars	$178.44 0.0%	$180.40 +1.1%	+15.1%	$9.34B	$1.53B	N/A	2,200
AMN AMN Healthcare Services	1.4035 of 5 stars	$27.65 0.0%	$25.29 -8.6%	+32.4%	$1.07B	$2.73B	N/A	2,664	Analyst Revision
VEEV Veeva Systems	4.6523 of 5 stars	$160.40 +0.1%	$276.52 +72.4%	-30.2%	$26.16B	$3.20B	29.65	7,928	Trending News Upcoming Earnings
RMD ResMed	4.8868 of 5 stars	$208.04 0.0%	$286.18 +37.6%	-16.9%	$30.31B	$5.15B	20.06	10,600	Positive News
DXCM DexCom	4.3338 of 5 stars	$72.10 flat	$82.21 +14.0%	-16.8%	$27.82B	$4.66B	30.81	11,000	Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MASI) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Masimo (MASI) Competitors

MASI vs. AMN, VEEV, RMD, DXCM, and STE

How does Masimo compare to AMN Healthcare Services?

Summary

How does Masimo compare to Veeva Systems?

Summary

How does Masimo compare to ResMed?

Summary

How does Masimo compare to DexCom?

Summary

How does Masimo compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI vs. The Competition

Masimo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Masimo (MASI) Competitors

MASI vs. AMN, VEEV, RMD, DXCM, and STE

How does Masimo compare to AMN Healthcare Services?

Do insiders and institutionals have more ownership in AMN or MASI?

Is AMN or MASI more profitable?

Does the media prefer AMN or MASI?

Which has more risk and volatility, AMN or MASI?

Do analysts prefer AMN or MASI?

Which has better valuation and earnings, AMN or MASI?

Summary

How does Masimo compare to Veeva Systems?

Which has more volatility and risk, MASI or VEEV?

Which has preferable earnings and valuation, MASI or VEEV?

Does the media prefer MASI or VEEV?

Is MASI or VEEV more profitable?

Do institutionals & insiders believe in MASI or VEEV?

Do analysts rate MASI or VEEV?

Summary

How does Masimo compare to ResMed?

Do analysts recommend RMD or MASI?

Which has better valuation & earnings, RMD or MASI?

Does the media favor RMD or MASI?

Is RMD or MASI more profitable?

Which has more risk and volatility, RMD or MASI?

Do insiders & institutionals have more ownership in RMD or MASI?

Summary

How does Masimo compare to DexCom?

Do analysts prefer DXCM or MASI?

Is DXCM or MASI more profitable?

Which has better valuation & earnings, DXCM or MASI?

Do institutionals and insiders hold more shares of DXCM or MASI?

Which has more risk and volatility, DXCM or MASI?

Does the media prefer DXCM or MASI?

Summary

How does Masimo compare to STERIS?

Is MASI or STE more profitable?

Do institutionals & insiders have more ownership in MASI or STE?

Which has better valuation & earnings, MASI or STE?

Which has more volatility and risk, MASI or STE?

Do analysts prefer MASI or STE?

Does the media refer more to MASI or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI vs. The Competition

Masimo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools